Study guide

5.2 Mechanisms of Action of Drugs and Biologics

NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the FPGEE 1.2 How to Use This Study Guide

2 Chapter 2: Foundational Biomedical Sciences I

2.1 Anatomy 2.2 Physiology 2.3 Biochemistry

3 Chapter 3: Foundational Biomedical Sciences II

3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases

4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry

4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions

5 Chapter 5: Pharmacology and Toxicology

5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes

6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics

6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics

7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems

7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics

8 Chapter 8: Public Health, Practice Management, and Biostatistics

8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods

9 Chapter 9: Professional Communication and Behavioral Aspects

9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice

10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment

10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education

11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care

11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine

12 Chapter 12: Clinical Sciences III — Evidence-Based Practice

12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability

13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products

13.1 Self-Care and Natural Products

5.2 Mechanisms of Action of Drugs and Biologics

Key Takeaways Explain This Topic AI

Drug mechanisms of action fall into six broad categories: receptor modulation, enzyme inhibition or activation, ion-channel blockade, transport inhibition, nucleic acid synthesis inhibition, and replacement therapy.

Autonomic drugs act through adrenergic (alpha, beta) and cholinergic (muscarinic, nicotinic) receptors; receptor selectivity determines both therapeutic use and adverse-effect profile.

Monoclonal antibody nonproprietary names encode target (-tu-, -li-, -ci-), source (-o-, -xi-, -zu-, -mu-), and class (-mab), allowing rapid identification of structure and indication.

Biosimilars are not generics — they are highly similar but not identical to reference biologics, carry residual immunogenicity risk, and require separate approval pathways.

Targeted oncology therapies exploit specific molecular lesions (kinase inhibitors) and immune checkpoints (PD-1, PD-L1, CTLA-4 antibodies) to improve selectivity over cytotoxic chemotherapy.

Last updated: July 2026

Categories of Mechanism of Action

A drug's mechanism of action (MOA) is the specific biochemical interaction through which it produces its pharmacological effect. MOAs can be grouped into six broad categories:

  • Receptor agonism or antagonism — beta-agonists, beta-blockers, antihistamines
  • Enzyme inhibition or activation — ACE inhibitors, statins (HMG-CoA reductase), allopurinol (xanthine oxidase)

Ion channel modulation — local anesthetics (Na+ channel blockade), CCBs (L-type Ca2+), sulfonylureas (K-ATP channel closure)

Transport inhibition — SSRIs (serotonin reuptake), proton-pump inhibitors (H+/K+ ATPase), loop diuretics (NKCC2)

  • Nucleic acid synthesis inhibition — fluoroquinolones (DNA gyrase), antifolates (trimethoprim, methotrexate)
  • Replacement or supplementation — insulin, levothyroxine, electrolytes, vitamins
  • Autonomic Pharmacology MOAs

The autonomic nervous system transmits signals via adrenergic and cholinergic receptors. Adrenergic agonists are classified by receptor selectivity: alpha-1 (phenylephrine — vasoconstriction), alpha-2 (clonidine — central sympatholysis), beta-1 (dobutamine — increased contractility), beta-2 (albuterol — bronchodilation). Adrenergic antagonists include nonselective alpha-blockers (phenoxybenzamine), selective alpha-1 blockers (tamsulosin), and beta-blockers whose selectivity for beta-1 (metoprolol) versus nonselectivity (propranolol) determines pulmonary and metabolic effects.

Cholinergic pharmacology uses muscarinic agonists (bethanechol for urinary retention, pilocarpine for glaucoma) and antagonists (atropine for bradycardia, oxybutynin for overactive bladder), plus nicotinic neuromuscular blockers (succinylcholine, rocuronium) used in anesthesia.

Major Drug Class MOAs and Therapeutic Uses

Drug class MOA Representative therapeutic use

ACE inhibitors (enalapril) Block conversion of Ang I to Ang II; reduce afterload and preload Hypertension, heart failure, diabetic nephropathy

ARBs (losartan) Block Ang II type-1 receptors Hypertension, heart failure (ACE-intolerant)

Beta-blockers (metoprolol) Block beta-1 adrenergic receptors; reduce heart rate, contractility, renin Post-MI, heart failure, hypertension, arrhythmia

  • Dihydropyridine CCBs (amlodipine) Block L-type Ca2+ channels in vascular smooth muscle Hypertension, angina
  • Statins (atorvastatin) Inhibit HMG-CoA reductase; lower LDL Atherosclerosis, primary and secondary prevention

Warfarin Inhibits vitamin-K epoxide reductase; reduces active factors II, VII, IX, X, protein C/S Anticoagulation (narrow TI)

DOACs (apixaban, rivaroxaban) Directly inhibit factor Xa; dabigatran inhibits IIa Anticoagulation (predictable, no routine monitoring)

  • SSRIs (sertraline) Inhibit serotonin reuptake at SERT Depression, anxiety
  • SNRIs (venlafaxine) Inhibit serotonin and norepinephrine reuptake Depression, neuropathic pain

Benzodiazepines (lorazepam) Potentiate GABA-A receptor (increase Cl- channel opening frequency) Anxiety, status epilepticus, alcohol withdrawal

  • Typical antipsychotics (haloperidol) D2 receptor antagonism Psychosis, delirium
  • Atypical antipsychotics (olanzapine) D2 plus 5-HT2A antagonism Schizophrenia, bipolar disorder
  • Opioids (morphine) Mu receptor agonism → reduced pain transmission Acute pain, palliative pain
  • Insulin Binds insulin receptor (tyrosine kinase) → GLUT4 translocation, anabolism Type 1 and type 2 diabetes

Metformin Inhibits mitochondrial complex I; activates AMPK → reduced gluconeogenesis Type 2 diabetes (first-line)

  • Sulfonylureas (glipizide) Close K-ATP channels on beta cells → insulin release Type 2 diabetes
  • Levothyroxine Thyroid hormone receptor agonist (nuclear) → transcriptional regulation Hypothyroidism

Beta-lactams (penicillins, cephalosporins, carbapenems) Bind PBPs; inhibit bacterial cell wall synthesis Bacterial infections (bactericidal)

Macrolides (azithromycin) Bind 50S ribosomal subunit; inhibit translocation Community-acquired pneumonia, atypicals

Fluoroquinolones (ciprofloxacin) Inhibit DNA gyrase and topoisomerase IV UTIs, GI infections, pseudomonal infections

Azoles (fluconazole) Inhibit fungal lanosterol 14-alpha-demethylase; deplete ergosterol Candidiasis, dermatophytes

Biologics and Biosimilars

Biologics are therapeutic products derived from living organisms — proteins, monoclonal antibodies, fusion proteins, cytokines, vaccines, cell and gene therapies. They are structurally complex, heat-sensitive, and parenterally administered because oral proteolysis destroys them.

Monoclonal antibodies (mAbs) are named using a four-part convention defined by the WHO and USAN: a prefix, a target substem, a source substem, and the stem "-mab." The target substem indicates what the antibody binds (e.g., -tu- for tumor, -li- for immune, -ci- for cardiovascular, -vi- for viral, -ba- for bacterial). The source substem reflects the antibody's protein composition: -o- for murine fragment (historical), -xi- for chimeric (murine variable + human constant), -zu- for humanized (murine CDRs grafted onto human framework), and -mu- for fully human. The stem -mab identifies the molecule as a monoclonal antibody. For example, trastuzumab = trastu- (prefix) + -tu- (tumor target) + -zu- (humanized) + -mab.

Fusion proteins combine an extracellular domain (e.g., a receptor ectodomain) with an Fc segment of IgG to extend half-life — etanercept (TNFR-Fc), abatacept (CTLA4-Fc). Cytokine modulators include recombinant cytokines (pegylated interferons, erythropoietin, filgrastim) and anti-cytokine antibodies (tocilizumab against IL-6R, canakinumab against IL-1 beta).

Biosimilars vs Generics

A generic is chemically identical to its small-molecule reference and can be substituted at the pharmacy without prescriber notification. A biosimilar is highly similar to its reference biologic with no clinically meaningful differences in safety, purity, or potency, but it is not identical — post-translational modifications, glycosylation patterns, and aggregate content differ microscopically. Biosimilars require a separate approval (FDA 351(k) pathway), may carry residual immunogenicity , and pharmacy-level substitution rules vary by state and product.

Targeted Therapies and Immunotherapy

Kinase inhibitors block oncogenic signaling by competing with ATP at the kinase active site — imatinib (BCR-ABL in CML), erlotinib and osimertinib (EGFR-mutant lung cancer), sunitinib (multi-kinase, renal and GIST). Immunotherapy releases immune checkpoints that tumors exploit to evade T-cell attack: PD-1 antibodies (pembrolizumab, nivolumab) and PD-L1 antibodies (atezolizumab) restore T-cell effector function, while CTLA-4 antibodies (ipilimumab) enhance T-cell priming in lymph nodes. Combination checkpoint blockade improves response in melanoma and renal cell carcinoma but increases immune-related adverse events (colitis, pneumonitis, hepatitis, endocrinopathies).

Loading diagram... Monoclonal Antibody Naming Convention (Trastuzumab)